Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older

Business Wire April 13, 2019

The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing

Benzinga.com  April 9, 2019

U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer

Business Wire April 4, 2019

AM Best Affirms Credit Ratings of Blue Whale Re Ltd.

Business Wire April 4, 2019

VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Business Wire April 3, 2019

Sangamo Soars Amid Multiple Development Pipeline Updates

Benzinga.com  April 2, 2019

Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy

Business Wire April 2, 2019

Cyclacel Drops After Study Supporting Cancer Drug's Mechanism Of Action

Benzinga.com  March 26, 2019

S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record at $223 Billion; 2018 Sets Record $806 Billion

PR Newswire March 25, 2019

The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company

Benzinga.com  March 20, 2019

PFIZER OBTIENT UNE OPTION EXCLUSIVE POUR ACQUÉRIR LA SOCIÉTÉ DE THÉRAPIE GÉNIQUE, VIVET THERAPEUTICS

Business Wire March 20, 2019

Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics

Business Wire March 20, 2019

Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer

PR Newswire March 19, 2019

Pfizer Invites Public to View and Listen to Webcast of April 30 Conference Call with Analysts

Business Wire March 19, 2019

A New Look For The Barron's 400 ETF

Benzinga.com  March 19, 2019

AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention

Business Wire March 17, 2019

Option-trading opportunities on Altaba Inc., Apple Inc., The Coca-Cola Co., Pfizer Inc., and Sea Limited

PR Newswire March 12, 2019

U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin®1

Business Wire March 11, 2019

U.S. Stocks Conclude Worst Week of '19

Press Releases March 8, 2019

AnTolRx Announces Pfizer Exercises Option To License Immune Tolerance Therapy For Potential Treatment Of Type 1 Diabetes

PR Newswire March 5, 2019